Faculty Bibliography

BACKGROUND & AIMS: The incidence and predictors of non-gastrointestinal (GI) adverse events (AEs) following colonoscopy are not well understood. We studied the effects of anti-thrombotic agents, cardiopulmonary comorbidities, and age on risk of non-GI AEs after colonoscopy. METHODS: We performed a retrospective longitudinal analysis to assess the diagnosis, procedure, and prescription drug codes in a United States commercial claims database (March 2010 - March 2012). Data from patients at increased risk (n=82,025; defined as patients with pulmonary comorbidities or cardiovascular disease requiring anti-thrombotic medications) were compared with data from 398,663 average-risk patients. In a 1:1 matched analysis, 51,932 patients at increased risk, examined by colonoscopy, were compared with 51,932 matched (based on age, sex, and comorbidities) patients at increased risk who did not undergo colonoscopy. We tracked cardiac, pulmonary, and neurovascular events 1-30 days after colonoscopy. RESULTS: Thirty days after outpatient colonoscopy, non-GI AEs were significantly higher in patients taking anti-thrombotic medications (7.3%; odds ratio [OR], 10.75; 95% CI, 10.13-11.42) or those with pulmonary comorbidities (1.8%; OR, 2.44; 95% CI, 2.27-2.62) vs average-risk patients (0.7%), and in patients 60-69 yrs old (OR, 2.21; 95% CI, 2.01-2.42) or 70 yrs or older (OR, 6.45; 95% CI, 5.89-7.06), compared to patients younger than 50 yrs. The 30-day incidence of non-GI AEs in patients at increased risk who underwent colonoscopy was also significantly higher than in matched patients at increased risk who did not undergo colonoscopy, in the anticoagulant group (OR, 2.31; 95% CI, 2.01-2.65) and in the chronic obstructive pulmonary disease group (OR, 1.33; 95% CI, 1.13-1.56). CONCLUSIONS: Increased number of comorbidities and older age (older than 60 years) are associated with increased risk of non-GI AEs after colonoscopy. These findings indicate the importance of determining comorbid risk and evaluating anti-thrombotic management prior to colonoscopy.

AIMS: Colorectal cancer (CRC) prevention by colonoscopy is often attributed to the early detection of adenomas, but lesions that go undetected can result in interval cancers. This is largely due to lesions that are hidden behind colonic folds that obscure endoscopic optics. The G-EYETM endoscope (Smart Medical Systems Ltd., Ra'anana, Israel) combines a forward-viewing endoscope with a permanently integrated balloon at the distal end, that when inflated flattens haustral folds, centralizes endoscope optics, and reduces bowel slippage. This provides improved visualization and increased detection of adenomas. Our study compares the adenoma detection rate of G-EYETM colonoscopy with that of Standard Colonoscopy.
METHOD(S): Patients (age >50) referred to colonoscopy for screening, surveillance, following positive FOBT, or due to change in bowel habits were randomized to G-EYETM colonoscopy or SC. Detected lesions were removed and sent for pathology. Adenoma detection rates were calculated.
RESULT(S): Nine hundred patients were enrolled in the study, of which 445 subjects were randomized to SC and 455 subjects were randomized to G-EYETM colonoscopy. Baseline parameters were similar in both groups. Results are presented in Table 1.
CONCLUSION(S): Our study shows that the G-EYETM endoscope has the potential to enhance the quality of CRC screening through increased adenoma detection. The G-EYETM detected not only small and diminutive adenomas, but a substantially higher number of advanced and large adenomas as well. Furthermore, increased detection by G-EYETM colonoscopy of sessile serrated adenomas, lesions strongly associated with CRC, can further reduce the incidents of interval cancers. (Table Presented)